Kimryn Rathmell, chair of medicine at Vanderbilt University Medical Center, received the Paragon Award for Research Excellence from the Doris Duke Foundation.
Fatemeh ArdeshirAndrew SrisuwananukornFatemeh Ardeshir and Andrew Srisuwananukorn, two presenters from the 23rd annual Young Investigator Symposium of the ECOG-ACRIN Cancer Research Group have received awards of distinction—a yearly tradition.Â
Henkel ValentineKimiko KriegerHenkel Valentine and Kimiko Krieger, two cancer scientists, were two of six postdoctoral researchers nationwide recently recognized as an IMPACT Fellow by the National Postdoctoral Association.
Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center is establishing a pilot program to open cell therapy clinical trials at Harris Health through Harris Health Ben Taub Hospital and Harris Health Smith Clinic to address cancer care disparities.
Stand Up To Cancer was recognized by Children’s Hospital of Philadelphia and the Society for Immunotherapy of Cancer for the contributions and achievements SU2C has made in raising funds and awareness to help cancer research.
An international phase III clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab.Â
Part 1 of the phase III RUBY trial of Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel) followed by dostarlimab as a single agent, compared to placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer produced positive primary results from a planned analysis.
Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia and experience higher rates of relapse and treatment toxicity. In recent decades, new therapies have improved outcomes for the general population, but outcomes for children with Down syndrome have lagged and have not been reported for contemporary treatment regimens.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found that the two test results differ because there are underlying subtle differences in the cells that make up an endometrial cancerous tumor.Â
A team of researchers from Japan and Singapore have found that integrating DNA methylation data with patients’ lifestyle and clinical data improves risk stratification for predicting gastric neoplasia (GN).
